Growers across the globe can now purchase dozens of cannabis strains designed to help conditions such as cancer, pain, PTSD and autism.
The Israeli Agtech startup RCK, which specialises in science-based cannabis genetics and breeding, has completed the first ever catalogue of cannabis strains, covering all the medical indications of the Israeli Medical Cannabis Agency (IMCA).
The company says the new move opens the path for mass marketing of medical cannabis by growers, who can now choose from dozens of strains in RCK’s catalogue.
Through its R&D efforts, RCK has developed technologies for creating new strains and stable cannabis hybrid seeds.
“Decoding the genetics of the cannabis plant paves the way for revolutionising the growing of cannabis,” says Shay Bar-Josef, co-founder and vice president for business development and marketing at RCK.
“Our complete catalogue of cannabis strains for medical uses will now enable every cannabis grower to purchase seedlings or mother plants that are suitable for specific diseases or various medical conditions and compete in the new eco-system that has been created.”
RCK is also offering growers the option to develop strains based on their specific customer specifications.
Alternatively, the growers can directly purchase from RCK’s range of strains developed by the company for exclusive cultivation.
The company has also embarked on field trials for growing hybrid seeds developed in the past three years.
Once the pilot is complete, RCK plans to commercially produce hybrid seeds from five different strains (three with high levels of THC and two with high CBD).
“In essence, we have opened the market for growers to grow and produce cannabis flowers that are suitable for every disease,” Bar-Joseph adds.
“This is great news for millions around the world who are waiting for pain relief from cannabis-based medical products.
“We are continuing to develop additional new strains for medical and commercial uses, and we can offer the development of unique strains for growers.”
RCK is currently in the process of raising funds from investors in an effort to expand its gene bank and R&D efforts, which are focused on developing unique cannabis strains for commercial growers.
The firm has already signed agreements for exporting cannabis strains and hybrid seeds to growers and distributors in several countries around the world as well as Israel.
In February, the company struck up a multi-million dollar agreement with Dutch seed company, SeedTech. As part of the deal, RCK devised a dedicated breeding plan to develop unique cannabis strains for medical and commercial use.
The company says its new hybrid seeds and breeding plans are now receiving interest from cannabis growers outside of Israel.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure